Sign In
Buy AGNPF
$0.248
-0.0513 (-17.12%)
At Close: Jul 31, 2026
Algernon Pharmaceuticals Announces Name Change to Algernon Health
07:00am, Thursday, 04'th Sep 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare
Algernon Pharmaceuticals closes private placement to fund Alzheimer's clinic initiative
08:31am, Friday, 25'th Jul 2025
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF), a Canadian clinical-stage drug development company, said it has closed the second tranche of a non-brokered private placement, raising total gross
Algernon Announces Closing of the Private Placement Financing
05:02pm, Thursday, 24'th Jul 2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000
05:29pm, Monday, 30'th Jun 2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Algernon Announces $1M Private Placement
07:00am, Tuesday, 27'th May 2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company”
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition
08:50pm, Thursday, 22'nd May 2025
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare an
VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare an
Algernon Announces Warrant Extension
07:47am, Monday, 05'th May 2025
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
07:00am, Tuesday, 08'th Apr 2025
VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical st
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
07:00am, Thursday, 06'th Mar 2025
VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical
VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical s
VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical s
Algernon Announces Warrant Extension
06:30pm, Monday, 04'th Nov 2024
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES
Algernon Pharmaceuticals Announces Closing of Private Placement
07:00am, Tuesday, 20'th Aug 2024
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANK
Algernon Pharmaceuticals Announces Increase to Private Placement
07:18am, Tuesday, 13'th Aug 2024
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANK
